Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01457547
Other study ID # 217744/094
Secondary ID
Status Completed
Phase Phase 4
First received October 13, 2011
Last updated August 4, 2016
Start date October 2003
Est. completion date May 2005

Study information

Verified date August 2016
Source GlaxoSmithKline
Contact n/a
Is FDA regulated No
Health authority Finland: FIMEA (Finnish Medicines Agency)
Study type Interventional

Clinical Trial Summary

The study will compare the immunogenicity and the reactogenicity of INFANRIX™ HEXA and HEXAVAC™ vaccines in a 3, 5 and 11 - 12 month vaccination schedule.


Recruitment information / eligibility

Status Completed
Enrollment 494
Est. completion date May 2005
Est. primary completion date May 2005
Accepts healthy volunteers Accepts Healthy Volunteers
Gender Both
Age group 8 Weeks to 15 Weeks
Eligibility Inclusion Criteria:

- A healthy male or female subject between 8 and 15 weeks of age at the time of the first vaccination.

- Written informed consent obtained from the parent or guardian of the subject prior to the study entry.

- Free of obvious health problems as established by medical history and clinical examination before entering into the study.

- Born after a normal gestation period between 36 and 42 weeks.

Exclusion Criteria:

- Use of any investigational or non-registered drug or vaccine other than the study vaccine within 30 days preceding the administration of the study vaccine, or planned use during the study period.

- Evidence of previous or intercurrent diphtheria, tetanus, pertussis, polio, hepatitis B and/or Hib vaccination or disease.

- Planned administration of a vaccine not foreseen by the study protocol since birth and during the period starting 30 days before the administration of the first dose and ending 30 days after the last dose of the three-dose primary vaccination course, with the exception of licensed Neisseria meningitides conjugate vaccines or Bacillus Calmette-Guérin (BCG) vaccine that can be given in between study visits or after the third visit, provided they are given preferably with a 4 weeks interval but not less than 3 weeks apart from the study vaccine doses.

- Chronic administration or planned administration of immuno-suppressants or other immune-modifying drugs since birth.

- Planned administration of immunoglobulins and/or any blood products since birth or planned administration during the period up to 30 days after the third dose of the primary vaccination course.

- Any confirmed or suspected immunosuppressive or immunodeficient condition, including human immunodeficiency virus (HIV) infection.

- History of seizures, progressive neurological disease or intra-cerebral haemorrhage.

- Major congenital defects or serious chronic illness.

- Acute febrile illness at the time of planned vaccination

- History of allergic disease or reactions likely to be exacerbated by any component of the study vaccine.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Single Blind (Subject), Primary Purpose: Prevention


Intervention

Biological:
DTPa-HBV-IPV/Hib Vaccine (INFANRIX™ HEXA)
Three doses administered intramuscularly
DTPa-HBV-IPV-Hib vaccine (HEXAVAC™)
Three doses administered intramuscularly

Locations

Country Name City State
Finland GSK Investigational Site Helsinki
Italy GSK Investigational Site Bari Puglia
Italy GSK Investigational Site Bologna Emilia-Romagna
Italy GSK Investigational Site Galatina (LE) Puglia
Italy GSK Investigational Site Maglie (LE) Puglia
Italy GSK Investigational Site Pavia Lombardia
Italy GSK Investigational Site Sassari Sardegna
Sweden GSK Investigational Site Linköping
Sweden GSK Investigational Site Örebro

Sponsors (1)

Lead Sponsor Collaborator
GlaxoSmithKline

Countries where clinical trial is conducted

Finland,  Italy,  Sweden, 

References & Publications (3)

Kilpi et al. Comparison of the immunogenicity and reactogenicity of two hexavalent DTPa-HBV-IPV/Haemophilus influenzae type b vaccines administered at 3, 5 and 11-12 months of age. Abstract presented at the 24th annual meeting of the European Society for Paediatric Infectious Diseases (ESPID), Basel Switzerland 03-05 May, 2006.

Kilpi TM, Silfverdal SA, Nilsson L, Syrjänen R, Belloni C, Desole M, Triban C, Storsaeter J, Soila M, Jacquet JM. Immunogenicity and reactogenicity of two diphtheria-tetanus-acellular pertussis-hepatitis B-inactivated polio virus-Haemophilus influenzae type b vaccines administered at 3, 5 and 11-12 months of age. Hum Vaccin. 2009 Jan-Feb;5(1):18-25. Epub 2009 Jan 2. — View Citation

Van Der Meeren O, Kuriyakose S, Kolhe D, Hardt K. Immunogenicity of Infanrix™ hexa administered at 3, 5 and 11 months of age. Vaccine. 2012 Apr 5;30(17):2710-4. doi: 10.1016/j.vaccine.2012.02.024. Epub 2012 Feb 18. — View Citation

Outcome

Type Measure Description Time frame Safety issue
Primary Immunogenicity with respect to the components of the study vaccine in terms of antibody concentrations Prior to the third primary vaccination dose ( Months 8-9) No
Secondary Immunogenicity with respect to the components of the study vaccine in terms of antibody concentrations One month after the second and third primary vaccination dose (Month 3 and Months 9-10) No
Secondary Immunogenicity with respect to the components of the study vaccine in terms of number of seroprotected subjects defined by antibody concentration Prior to and one month after the third primary vaccination dose ( Months 8-9 and Months 9-10) No
Secondary Immunogenicity with respect to the components of the study vaccine in terms of number of seropositive subjects Prior to and one month after the third primary vaccination dose ( Months 8-9 and Months 9-10) No
Secondary Occurrence of solicited symptoms Within 4 days (Day 0 -Day 3) after each vaccine dose No
Secondary Occurrence of a grade "3" solicited symptoms Within 4 days (Day 0 -Day 3) after each vaccine dose No
Secondary Occurrence of unsolicited adverse events Within 31 days after any vaccination No
Secondary Occurrence of Serious Adverse Events Throughout the entire study up to (Month 0 to Month 9-10) and including 30 days after last vaccination (Month 9-10) No
See also
  Status Clinical Trial Phase
Completed NCT01182311 - Duration of Long-term Immunity After Hepatitis B Virus Immunization
Completed NCT04971928 - Phase 1 Study of GSK3228836 Pharmacokinetics in Participants With Hepatic Impairment Phase 1
Completed NCT03285620 - A Study of AL-034 to Evaluate the Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses in Healthy Participants Phase 1
Completed NCT01884415 - Phase III, Study to Evaluate the Efficacy of Two Different HBV Vaccination Schemes in Patients With Hepatic Cirrhosis Phase 3
Recruiting NCT05404919 - Utilization of Hepatitis B Virus NAT+ Donors for Hepatitis B Vaccinated Lung Transplant Candidates Phase 2
Completed NCT02153320 - Study to Evaluate the Persistence of the Cellular and Humoral Immune Response Following Vaccinations With GlaxoSmithKline (GSK) Biologicals' Candidate Vaccines Containing HBsAg and Different Adjuvants in Healthy Adult Volunteers Phase 1
Completed NCT00352963 - Immunogenicity & Safety Study of Combined/Separate Vaccine(s) Against Common Diseases in Infants (2,4,6 Months of Age). Phase 3
Completed NCT03567382 - Arresting Vertical Transmission of Hepatitis B Virus Phase 4
Not yet recruiting NCT04056728 - A Phase IV Study to Assess the Safety of EupentaTM Inj Phase 4
Not yet recruiting NCT03604016 - Study to Assess Efficacy of Besifovir and L-carnitine in Chronic Hepatitis B Patients With Nonalcoholic Fatty Liver Phase 4
Completed NCT00753649 - Immunogenicity and Safety of GSK Biologicals' Infanrix Hexa in Infants Phase 4
Recruiting NCT03027258 - Point-of-Delivery Prenatal Test Results Through mHealth to Improve Birth Outcome N/A
Completed NCT02540538 - Safety and Immunogenicity of HBAI20 Hepatitis B Vaccine in Naive Adults and Non-responders Phase 1
Terminated NCT02604199 - A Multi-dose Study of ARC-520 in Patients With Hepatitis B 'e' Antigen (HBeAg) Negative, Chronic Hepatitis B Virus (HBV) Infection Phase 2
Completed NCT02421666 - A Comparative Trial of Improving Care for Underserved Asian Americans Infected With HBV N/A
Completed NCT02169674 - Hepatitis B Booster Study in Adolescence Phase 4
Completed NCT01917357 - A Comparison of the Immunogenicity and Safety of Quinvaxem in Mono-dose Vials and Uniject Phase 3
Completed NCT01368497 - Entecavir/Pegylated Interferon in Immune Tolerant Children With Chronic Hepatitis B Virus (HBV) Infection Phase 3
Completed NCT01732354 - Study for Consolidation Period of Chronic Hepatitis B
Recruiting NCT01462981 - Cohort of Hepatitis B Research of Amsterdam N/A